Literature DB >> 8208733

Enterokinase.

N S Mann1, S K Mann.   

Abstract

Enterokinase is a glycoprotein and is now designated enteropeptidase (E.C.3.4.4.8.). It is present in the duodenal and jejunal mucosa. Pancreatic proteolytic enzymes are secreted as proenzymes. Enterokinase converts trypsinogen to trypsin in the duodenal lumen. Duodenopancreatic reflux of duodenal enterokinase may be important in the pathogenesis of experimental and clinical acute pancreatitis. Congenital enterokinase deficiency is a distinct clinical entity characterized by diarrhea, failure to thrive, hypoproteinemia, and edema. Acquired enterokinase deficiency may occur in some diffuse small bowel diseases. Steatorrhea of celiac spruce may be due partly to the fact that deficiency of secretin and cholecystokinin may interfere with the action of enterokinase. The interrelationship between secretin, cholecystokinin, enterokinase, and bile salts is not completely understood.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8208733     DOI: 10.3181/00379727-206-43728

Source DB:  PubMed          Journal:  Proc Soc Exp Biol Med        ISSN: 0037-9727


  10 in total

1.  Gallbladder and pancreatic dysfunction in celiac disease.

Authors:  N S Mann
Journal:  Dig Dis Sci       Date:  1995-11       Impact factor: 3.199

Review 2.  Corin in clinical laboratory diagnostics.

Authors:  Ningzheng Dong; Shenghan Chen; Wei Wang; Yiqing Zhou; Qingyu Wu
Journal:  Clin Chim Acta       Date:  2011-11-07       Impact factor: 3.786

Review 3.  Autodigestion: Proteolytic Degradation and Multiple Organ Failure in Shock.

Authors:  Angelina E Altshuler; Erik B Kistler; Geert W Schmid-Schönbein
Journal:  Shock       Date:  2016-05       Impact factor: 3.454

Review 4.  Membrane-anchored serine proteases in health and disease.

Authors:  Toni M Antalis; Thomas H Bugge; Qingyu Wu
Journal:  Prog Mol Biol Transl Sci       Date:  2011       Impact factor: 3.622

5.  SCO-792, an enteropeptidase inhibitor, improves disease status of diabetes and obesity in mice.

Authors:  Hiroaki Yashiro; Kenichi Hamagami; Hideyuki Hiyoshi; Jun Sugama; Kazue Tsuchimori; Fuminari Yamaguchi; Yusuke Moritoh; Minoru Sasaki; Tsuyoshi Maekawa; Yukio Yamada; Masanori Watanabe
Journal:  Diabetes Obes Metab       Date:  2019-07-02       Impact factor: 6.577

6.  Enteropeptidase inhibitor SCO-792 effectively prevents kidney function decline and fibrosis in a rat model of chronic kidney disease.

Authors:  Yuko Katayama; Jun Sugama; Tomohisa Suzuki; Yoshimasa Ishimura; Akihiro Kobayashi; Yusuke Moritoh; Masanori Watanabe
Journal:  Nephrol Dial Transplant       Date:  2021-03-29       Impact factor: 5.992

Review 7.  Small and Large Intestine (I): Malabsorption of Nutrients.

Authors:  Miguel A Montoro-Huguet; Blanca Belloc; Manuel Domínguez-Cajal
Journal:  Nutrients       Date:  2021-04-11       Impact factor: 5.717

8.  The Global Status and Trends of Enteropeptidase: A Bibliometric Study.

Authors:  Xiaoli Yang; Hua Yin; Lisi Peng; Deyu Zhang; Keliang Li; Fang Cui; Chuanchao Xia; Haojie Huang; Zhaoshen Li
Journal:  Front Med (Lausanne)       Date:  2022-02-10

9.  Bibliometric Analysis of Cathepsin B Research From 2011 to 2021.

Authors:  Xiaoli Yang; Hua Yin; Deyu Zhang; Lisi Peng; Keliang Li; Fang Cui; Chuanchao Xia; Zhaoshen Li; Haojie Huang
Journal:  Front Med (Lausanne)       Date:  2022-07-06

10.  Enteropeptidase inhibition improves kidney function in a rat model of diabetic kidney disease.

Authors:  Jun Sugama; Yuko Katayama; Yusuke Moritoh; Masanori Watanabe
Journal:  Diabetes Obes Metab       Date:  2020-10-06       Impact factor: 6.577

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.